SF3B1 and neoplasm: We previously mentioned that SF3B1 mutant MDS often undergoes aberrant activation of the DNA damage response and that this genotoxic damage can be repaired using DNA damaging agents (e.g., etoposide) or synthetic lethal small molecule inhibitors (e.g., PARP inhibitors) by selective targeting of tumor cells carrying SF3B1K700E mutation is accomplished by selective targeting of tumor cells carrying the mutation (58).